清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Primary Hepatic Small Cell Carcinoma: Two Case Reports, Molecular Characterization and Pooled Analysis of Known Clinical Data.

恶性肿瘤 医学 危险系数 原发性肿瘤 肿瘤科 病理 内科学 置信区间 癌症 转移
作者
Aditi Shastri,Pavlos Msaouel,Cristina Montagna,Sherry White,Maria Delio,Kunjan Patel,Karenza Alexis,Marianna Strakhan,Tarek N. Elrafei,Louis Juden Reed
出处
期刊:PubMed 卷期号:36 (1): 271-7 被引量:6
链接
标识
摘要

Primary hepatic small cell carcinoma (HSCC) is a rare malignancy that has previously been described in only few case reports. The clinicopathological course, natural history, molecular markers and ideal treatment strategy for this tumor have not been fully elucidated. Herein, we report on two cases of spontaneously arising, metastatic primary HSCC that were treated at our Institution. Both patients succumbed to their disease within two months of initial presentation. Both cases underwent postmortem examination and no evidence of a pulmonary or other non-hepatic small cell primary was found. Unlike pulmonary small cell tumors, these two hepatic primaries showed only locoregional spread and very few distant metastases. Formalin-fixed samples were obtained at autopsy and sequenced using single-nucleotide polymorphism arrays and whole-genome sequencing. Four mutations in the epidermal growth factor receptor (EGFR) gene known to be associated with response to tyrosine kinase inhibitors (TKIs) were detected in one of the two HSCC samples. A systematic review and pooled analysis of all previously reported cases of primary HSCCs was conducted. The median overall survival was estimated at 4 months. Surgical resection was significantly associated with longer overall survival (hazard ratio =0.13, 95% confidence interval=0.03-0.69). Although several case reports of primary HSCC have been reported prior to this publication, to our knowledge this is the first time that molecular and systematic analysis has been conducted in order to more fully characterize this rare disease. Our results indicate that surgical resection, when feasible, may be a valid option in primary HSCC, and that some tumors may respond to TKIs against EGFR.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助科研通管家采纳,获得10
6秒前
房天川完成签到 ,获得积分10
32秒前
wushuimei完成签到 ,获得积分10
50秒前
魔幻友菱完成签到 ,获得积分10
55秒前
田様应助evermore采纳,获得10
1分钟前
愉快的溪流完成签到 ,获得积分10
1分钟前
1分钟前
蜜意发布了新的文献求助10
1分钟前
娟子完成签到,获得积分10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
Emperor完成签到 ,获得积分0
2分钟前
深情安青应助蜜意采纳,获得10
2分钟前
孙老师完成签到 ,获得积分10
2分钟前
2分钟前
wang5945完成签到 ,获得积分10
2分钟前
evermore完成签到,获得积分10
2分钟前
evermore发布了新的文献求助10
2分钟前
2分钟前
Crystal发布了新的文献求助10
2分钟前
2分钟前
2分钟前
无畏阿玲发布了新的文献求助10
2分钟前
赘婿应助无畏阿玲采纳,获得10
2分钟前
3分钟前
Wu发布了新的文献求助10
3分钟前
山是山三十三完成签到 ,获得积分10
3分钟前
打打应助你能行采纳,获得10
3分钟前
研友_VZG7GZ应助Wu采纳,获得10
3分钟前
3分钟前
幸运星完成签到 ,获得积分10
3分钟前
3分钟前
无畏阿玲完成签到,获得积分10
3分钟前
顾矜应助鲜艳的手链采纳,获得10
4分钟前
4分钟前
蜜意发布了新的文献求助10
4分钟前
手术刀完成签到 ,获得积分10
4分钟前
可爱的函函应助Crystal采纳,获得10
5分钟前
5分钟前
Crystal发布了新的文献求助10
5分钟前
blueskyzhi完成签到,获得积分10
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
T/SNFSOC 0002—2025 独居石精矿碱法冶炼工艺技术标准 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6042751
求助须知:如何正确求助?哪些是违规求助? 7798075
关于积分的说明 16237482
捐赠科研通 5188432
什么是DOI,文献DOI怎么找? 2776491
邀请新用户注册赠送积分活动 1759547
关于科研通互助平台的介绍 1643073